Navigation Links
Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds

-- CancerCare offers five questions to help women learn about breast cancer therapy advances --

NEW YORK, June 12, 2007 – According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment. Fewer than one out of four (23 percent) women ages 50-65 have heard of new therapies for breast cancer, revealing a gap between awareness and information that women can use toward better treatment.

"These survey results suggest that many women still lack essential disease treatment information, which reinforces the need for women to educate themselves to help get the best treatment," said Diane Blum, MSW, executive director of CancerCare. "While great progress has been made in breast cancer awareness through public education and increased media coverage, women with breast cancer would benefit from more information about advances in treatments after surgery."

According to the survey, nearly all respondents were aware of chemotherapy and radiation. However, fewer than one out of four had heard of newer therapies such as aromatase inhibitors or monoclonal antibodies, nor were they informed about their benefits.

Doctor-patient dialogue is vital

If diagnosed, the majority of respondents said they would actively work with their doctor to identify the proper treatment. The survey also found that 71 percent of women would research the condition on their own in addition to discussing treatment options with their doctor. However, 86 percent were not certain they would know what questions to ask.

"Communication between the patients and their physicians is so important because it empowers them to take an active role
'"/>




Page: 1 2 3

Related medicine technology :

1. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
2. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
5. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
6. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
9. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
10. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
11. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
Post Your Comments:
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:12/26/2014)... December 26, 2014 Cooking and ... 3.1 out of 5. This score reflects slightly positive ... of product specialization, low switching costs and a low ... by the low availability of substitutes for cooking and ... of steel and aluminum, key inputs in the production ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... University and Harvard University have collaboratively developed a new theoretical ... sequences, even though there are many obstacles in the way ... in the scientific journal Nature Physics . , In ... so that different cells carry out the right tasks at ...
... important tasks of the immune system is to identify what ... then the body,s own structures will be attacked, the result ... mellitus type 1 or multiple sclerosis. The only way to ... that turn against the body,s own tissue in other ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced that shareholders ... of Tepnel by Gen-Probe by the requisite majorities at Court ... of Tepnel shareholders voted in favor of the acquisition, which ... as a "scheme of arrangement" under English law. The ...
... Probiotic Works Naturally to Restore Oral HealthCHICAGO, March ... and Butler(R) brand products, has introduced GUM(R) PerioBalance(TM), ... for oral health. GUM(R) PerioBalance(TM) is available online ... GUM(R) PerioBalance(TM) e-store ( www.periobalance.com ) and at ...
... Health Segment Increases Annual RevenueLOVELAND, Colo., March 16 ... ("Heska" or the "Company") today reported financial results ... December 31, 2008, and year ended December 31, ... , "The poor economic environment had an impact ...
... led by Clifford Goodman, PhD, at the NCCN 14th Annual ... Cancer Care." The panel of experts tackled the spectrum of ... benefit to patients of some of the latest cancer treatments ... Oncology is an area of rapid growth, both in terms ...
Cached Medicine News:Health News:Important new model shows how proteins find the right DNA sequences 2Health News:Dendritic cells ensure immune tolerance 2Health News:Dendritic cells ensure immune tolerance 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 2Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 3Health News:Heska Announces Q4 and Annual 2008 Results 2Health News:Heska Announces Q4 and Annual 2008 Results 3Health News:Heska Announces Q4 and Annual 2008 Results 4Health News:Heska Announces Q4 and Annual 2008 Results 5Health News:Heska Announces Q4 and Annual 2008 Results 6Health News:Heska Announces Q4 and Annual 2008 Results 7Health News:Heska Announces Q4 and Annual 2008 Results 8Health News:Heska Announces Q4 and Annual 2008 Results 9Health News:Heska Announces Q4 and Annual 2008 Results 10Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 2Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 3Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 4Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 5
Quality control ampoules are specifically developed for Radiometers analyzers , Different parameter profiles (different combinations of blood gases, oximetry, electrolytes and metabolites) , Co...
... In interventional cardiology, accurate ... role, particularly in determining the ... With Interventional Cardiac 3-D (IC3D), ... imaging tool, clinicians are now ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... Hybrid Imaging in Cardiology ... imaging solutions in cardiology. ... coronary CT angiography imaging combined ... Symbia TruePoint SPECTCT combines ...
Medicine Products: